Home › Multiple Myeloma › Connecticut
Multiple Myeloma clinical trials in Connecticut
17 studies for Multiple Myeloma are looking for participants at sites in Connecticut.
Cities in Connecticut
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Yale University, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07555938Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06993675A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Connecticut, Farmington
- Yale New Haven Hospital, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Connecticut Health Center, Farmington
- Yale Cancer Center, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Yale University School of Medicine /ID# 272447, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06953960Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- Yale University, New Haven
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06465316A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Connecticut Health Center, Farmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Yale University School Of Medicine, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Saint Vincent's Medical Center (SVMC), Bridgeport
- Hartford Hospital, Hartford
- Midstate Medical Center (MSMC), Meriden
- and 4 more
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Yale New Haven Hospital-Smilow Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06988488A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Norwich
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07227311Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- and 11 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- and 11 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 18, 2026 · NCT06153251From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.